TRUB1: A Potential Cancer Treatment Target (G142940)

Target Name: TRUB1

NCBI ID: G142940

TRUB1

TRUB1: A Potential Cancer Treatment Target

TRUB1 (Tumor suppressor gene 1) is a gene that has been identified as a potential drug target for cancer treatment. It is located on chromosome 17 and has been shown to play a role in regulating cell growth and division.

TRUB1 is a tumor suppressor gene, which means that it is capable of preventing the formation of cancer cells. It is thought to work by inhibiting the activity of the cell division cycle, which is responsible for the rapid growth and development of cancer cells.

One of the ways that TRUB1 is thought to work is by inhibiting the activity of the protein p21, which plays a key role in regulating cell growth and division. p21 is a transcription factor that is activated when the cell division cycle is in G1 phase, and it is thought to help ensure that the cell divides only once.

Research has shown that TRUB1 is often expressed in human cancer cells, and that it is a good candidate for targeting with drugs. In fact, several studies have suggested that TRUB1 may be a useful biomarker for cancer diagnosis and treatment, particularly in cases where the cancer is aggressive or has recurred.

Another potential mechanism by which TRUB1 may work is by inhibiting the activity of the protein p53, which is a well-known tumor suppressor gene that is located on chromosome 6. P53 is responsible for monitoring the damage caused by mutations in DNA, and it is thought to help ensure that the cell is able to repair the damage before the cell becomes cancerous.

TRUB1 has also been shown to play a role in regulating the expression of other genes that are involved in cell growth and development. For example, it has been shown to suppress the activity of the gene p16, which is associated with the development of cancer.

In addition to its potential role in cancer treatment, TRUB1 is also of interest to researchers because of its location on chromosome 17. This suggests that it is likely to be expressed in many different types of cancer, and that it may be a useful target for personalized medicine.

Overall, TRUB1 is a promising candidate for drug targeting in cancer treatment. Further research is needed to fully understand its mechanisms of action and to determine its potential as a drug.

Protein Name: TruB Pseudouridine Synthase Family Member 1

Functions: Pseudouridine synthase that catalyzes pseudouridylation of mRNAs and tRNAs (PubMed:28073919, PubMed:31477916, PubMed:32926445). Mediates pseudouridylation of mRNAs with the consensus sequence 5'-GUUCNANNC-3', harboring a stem-loop structure (PubMed:28073919, PubMed:31477916). Constitutes the major pseudouridine synthase acting on mRNAs (PubMed:28073919). Also catalyzes pseudouridylation of some tRNAs, including synthesis of pseudouridine(55) from uracil-55, in the psi GC loop of a subset of tRNAs (PubMed:32926445, PubMed:33023933). Promotes the processing of pri-let-7 microRNAs (pri-miRNAs) independently of its RNA pseudouridylate synthase activity (PubMed:32926445). Acts by binding to the stem-loop structure on pri-let-7, preventing LIN28-binding (LIN28A and/or LIN28B), thereby enhancing the interaction between pri-let-7 and the microprocessor DGCR8, which mediates miRNA maturation (PubMed:32926445)

The "TRUB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRUB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets